Securities code: Shanxi Zhendong Pharmaceutical Co.Ltd(300158) securities abbreviation: Shanxi Zhendong Pharmaceutical Co.Ltd(300158) Shanxi Zhendong Pharmaceutical Co.Ltd(300158) investor relations activity record
No.: 2022001
□ specific object research □ analyst meeting
□ media interview ☑ Performance presentation meeting
Investor relations activities
□ press conference □ Roadshow
category
□ site visit
□ others (please specify other activities in words)
Names of participating units, Shenzhen value online, Shanghai Securities, Huaan Securities Co.Ltd(600909) and other institutions and names of more than 170 individual investors.
Time: April 12, 2022
Location: Q & a platform for performance exchange meeting
Chairman Li Anping
Independent director Qiao Yanjiang
Receptionist and general manager of listed company Yang Lianmin
Deputy general manager Lei Zhenhong
Chief financial officer Liu Changlu
Secretary of the board of directors Zhou Hongjun
1. Is there a blockbuster new drug on the market this year? What is the sales prospect of dafixin? Progress of hair dye research and development? The company’s vision?
Investor relations activities
① Zd03, lalotasai and other class I new drugs are under research, and there is no major content introduction this year
Pounds of new drugs on the market. ② The market scale of hair medical services in China is expected to increase from 18.4 billion yuan in 2020 to 138.1 billion yuan in 2030, with a compound growth rate of 22.3%. his
In, the market of medical care and fixation services increased from 5 billion yuan to 62.5 billion yuan, with a 10-year compound growth rate of 28.7%, which has a lot of room for growth. ③ Pure plant hair dye is under research and development, and the company will make a timely announcement in case of disclosure. ④ The company is strategically positioned as a “marketing innovation” enterprise. On the basis of 8 pipelines including tumor, dermatology, cardio brain, urology and digestion, continue to implement strategic slimming, focus on the four fields of “hair dermatology, tumor traditional Chinese medicine, chemical raw materials and traditional Chinese medicine”, focus on the goal of “only being the first in the country”, pay close attention to imitation, innovative research and development, and build a Chinese head enterprise of Dermatology and an expert in the manufacture of traditional Chinese medicine for head tumor; Lock the upstream industrial chain, create a chemical API production base, and realize the self-production of raw materials for core products and the main production of scarce and bulk APIs; Give full play to the advantages of genuine medicinal materials, build a base for raw materials of traditional Chinese medicine, and form a development platform for the whole industrial chain of high-quality traditional Chinese Medicine Integrating cultivation, primary processing, warehousing and intensive processing. At the same time, deeply tap dormant varieties and make a big fuss in the OTC field with the brand operation experience of “Langdi calcium” and the resources of chain pharmacies; Timely acquire the product number of matching marketing pipeline, enrich the core product line, give full play to the existing production capacity, and strive to make the enterprise produce at full capacity without investment.
2. After the company pays 109% of the profits, what is the plan for the company to sell the cost recovered by the subsidiary of Randy in the next step?
The company carries out corresponding investment work such as document number acquisition and enterprise merger and acquisition in the fields of hair dermatology, tumor traditional Chinese medicine, chemical raw materials and traditional Chinese medicine. At the same time, through the transformation and optimization of its own production line, give full play to the existing production capacity, realize full capacity production and improve asset efficiency without external investment.
3. Does the company have any intention of M & A or acquisition of enterprises or industries?
The company focuses on the four fields of hair dermatology, tumor traditional Chinese medicine, chemical raw materials and traditional Chinese medicine, and carries out investment work such as corresponding document number purchase and enterprise M & A around the above strategy.
4. What is the company’s key work deployment in 2022?
2022 is the “new year of marketing innovation” of the company, and also the beginning year of building the enterprise strategy of “marketing innovation” in the future. Focusing on the business principles of “subdividing level, paying close attention to data, spreading terminals and improving customer service”, we will continue to refine the 33 mode to achieve “subdivision level” in all fields of personnel, business, cost and policy. Establish and improve various databases of customers (users), consumers, personnel, materials, costs and expenses, and lay a good foundation for next year’s “data year” through “paying close attention to data”; Establish the awareness that the terminal is king, and the five marketing centers of clinical, OTC, grass-roots, medical trade and e-commerce “widely spread the terminal” around their respective channels to realize the full coverage of the company’s product market; Relying on the customer service center, focus on the different needs of various customers to “expand customer service”, so as to achieve accurate promotion and considerate service.
5. How to develop national treasure traditional Chinese medicine in the next step?
The company gives full play to the advantages of genuine medicinal materials, builds a raw material base of traditional Chinese medicine, and forms a development platform of the whole industrial chain of high-quality traditional Chinese Medicine Integrating seed and seedling breeding, traditional Chinese medicine planting, primary processing, warehousing and intensive processing; Establish “Zhendong China Australia molecular traditional Chinese medicine research center” jointly with the University of Adelaide, focusing on the research on the action mechanism of Yanshu and other Chinese patent medicines and the genuine research of medicinal materials; Carry out in-depth research and secondary development of 13 traditional Chinese medicines; Cooperate with Anderson Cancer Center of the United States to complete the FDA registration of Yanshu and accelerate the increase of the registration and declaration of indications for radiation pneumonia; The company carries out corresponding investment work such as document number acquisition and enterprise merger and acquisition around the fields of tumor traditional Chinese medicine.
6. Please introduce the company’s potential products and related plans.
Dafixin minoxidil liniment takes advantage of the company’s marketing advantages in clinical, OTC, e-commerce and other terminals, multi-media integration, brand building, differential promotion and interactive communication. Shuxuening injection has entered the centralized collection of Chinese patent medicine and will seize market share and improve sales revenue through commercial interception and terminal pull. Xihuang Pill will continue to expand terminals, strengthen development and achieve rapid growth.
7. What are the advantages of the company’s product industry chain? What is the embodiment of business performance?
In terms of R & D, the company has two R & D centers: Beijing Pharmaceutical Research Institute and Changzhi science and technology center. Beijing Pharmaceutical Research Institute focuses on innovative drugs, generic drugs and traditional Chinese medicine; The science and technology center focuses on liposome high-end preparations and APIs, forming an independent and complementary R & D system. The company and the University of Adelaide jointly established the “Zhendong China Australia molecular traditional Chinese medicine research center”, focusing on the research on the mechanism of action of Yan Shu and other Chinese patent medicines and the genuine research of medicinal materials. In production, all production enterprises carry out dosage form integration according to the principle of producing professional dosage forms with technical expertise, and implement the internal transfer of document numbers and varieties. Start dormant varieties and increase sales according to the marketing strategy. In terms of marketing, the company has a strong marketing network, covering 498 cities and 8403 grade hospitals in China, as well as major chain pharmacies and grass-roots markets.
In 2021, the company realized an operating revenue of 50937763 million yuan, a year-on-year increase of 5.07%.
8. What is the market share of hair care products at present and whether the market will have a scale of 100 billion in the future?
The market scale of hair medical services in China is expected to increase from 18.4 billion yuan in 2020 to 138.1 billion yuan in 2030, with a compound growth rate of 22.3%. Among them, the market of hair transplant medical services increased from 13.4 billion yuan to 75.6 billion yuan, with a 10-year compound growth rate of 18.9%; The market of medical care and fixation services increased from 5 billion yuan to 62.5 billion yuan, with a 10-year compound growth rate of 28.7%. Compared with hair transplantation, hair care, scalp care, etc. have the advantages of wide customer base, easy acceptance, high re purchase, and have greater growth space. 9. How did the net profit of the non main company decrease year-on-year?
The company continues to implement the strategy of slimming down, focusing on the four fields of “hair dermatology, tumor traditional Chinese medicine, chemical raw materials and traditional Chinese medicine”, increasing investment, promoting R & D and innovation, starting dormant varieties, strengthening scientific and technological cooperation, consolidating the advantages of traditional Chinese medicine, challenging traditional innovative marketing tactics, innovating thinking, building brand chain, enhancing core competitiveness, striving to improve business performance and repay the majority of investors.
10. Does the company support anti epidemic drugs during the epidemic?
Since the outbreak of the epidemic at the beginning of the year, the company has donated various epidemic prevention drugs, urgently needed prevention and control supplies and disinfection supplies, including Yinqiao Jiedu Capsule, to more than 900 medical and health institutions in 28 provinces across the country, with a cumulative value of more than 15 million yuan. At present, the overall donation work is still continuing.
11. Is there a performance forecast in the first quarterly report of 22 years? How was your company’s performance in the first quarter?
Please pay timely attention to the first quarter report released by the company on April 22.
12. The company made such a high profit last year because of the sale of Randy’s subsidiary. Will there be momentum to continue this profit this year? Where do the profits come from, selling subsidiaries or acquiring other companies?
The company will strive to do a good job in business, continuously improve the company’s business performance, and formulate corresponding dividend plans according to the actual business performance and relevant rules and regulations.
13. Does the company have a market value management plan?
The company believes that the core of market value management is to do a good job in business. The company focuses on the four fields of “hair dermatology, tumor traditional Chinese medicine, chemical raw materials and traditional Chinese medicine”, strives to improve business performance and actively repay investors.
14. As for securities, the P / E ratio of the same industry is so low. Why didn’t the company do some positive and normal guidance? Let investors have more enthusiasm to grow and benefit with the company!
Thank you for your suggestions. The company will strengthen brand promotion, value communication and investor interaction, improve market awareness and actively repay investors.
15. Number of shareholders of the company on March 31, 2022?
Dear investors! Please send your shareholder Certificate (ID card and shareholder account card) to the company email (zqb@ zdjt. Co m). After verifying your shareholder identity, the company will reply your latest number of shareholders by email or telephone (03558096012) within 3 working days.
16. What are the reasons for the sharp decline in the company’s non net profit deduction and the approximate amounts affected?
① In October 2021, the company sold Langdi pharmaceutical, which affected the deduction of non net profit; ② R & D investment in 2021 increased compared with the same period; To sum up, the deduction of non net profit decreased significantly.
17. Factors affecting the deduction of non profits, in addition to the additional investment of 80 million in R & D and the payment of about 50 million consulting fees for the sale of subsidiaries, are there other factors, such as tax, and how much is the impact?
In addition to the above reasons, it is also affected by factors such as the increase in cost caused by packaging materials and energy expenses, the decrease in price and gross profit margin caused by consistency evaluation, the increase in management and R & D expenses, and the decrease in the proportion of sales after the sale of Randy calcium.
18. Detailed categories and reasons for the loss of 150 million in the fourth quarter of 2021. ① In October 2021, the company sold Lundy pharmaceutical, which affected the operating profit in the fourth quarter; ② R & D investment in the fourth quarter increased compared with the first three quarters; To sum up, it led to a loss in the fourth quarter.
19. Why are the selling expenses so high?
Sales expenses are the guarantee to ensure that the company’s sales reach the target. The company has a self-supporting sales team of thousands of employees, focusing on clinical terminals, integrating market resources through academic promotion, focusing on the professional role of expert committees at all levels. The company has many varieties. Each variety needs to carry out academic promotion in a wide range, deep degree and great strength, and the corresponding expenses are also high.
20. The dividend rate of the company in 2021 is 105%, and all the money earned last year is divided. How much cash does the company have to meet the needs of this year?
The company has enough cash for operation and future development needs.
21. How much profit can Randy make for the company in the previous year?
Please pay attention to the 2020 annual report for detailed data.
22. In 2021, the company’s sales of traditional Chinese medicine was 586 million, and what was the gross profit margin? There are many varieties of traditional Chinese medicine, and the gross profit margin of each variety is different.
23. Will the dividend scheme given in the annual report be changed due to the issuance of the inquiry letter or other factors? Can the company maintain such a dividend scheme if there are no unexpected factors in the business plan formulated by the company this year?
The dividend plan of the company needs to be considered by the annual general meeting of shareholders. The future dividend situation also needs to be determined according to the actual operating performance of the company.
24. After the company put forward the dividend plan, the stock price rose, and the major shareholders took the opportunity to reduce their holdings and cash out. Now it is said that the shareholders’ meeting on April 22 considered whether there is interest transfer? Cheating small and medium-sized investors?
The dividend plan of the company can only be implemented after being deliberated and approved by the annual general meeting of shareholders. Major shareholders implement the share reduction plan due to their own capital needs. Major shareholders strictly abide by the requirements of relevant laws and regulations, reduce their shares, and timely fulfill the obligation of information disclosure.
25. Although the company’s share price belongs to market behavior, it has fallen all the way since the company issued a dividend of 27 yuan for 10 shares. Why has it not been recognized by the market? What plan does the company have?
The stock price is affected by many factors such as the international environment, macro-economy and industrial policies. The management of the company will seriously do a good job in various business work, strive to improve business performance and repay the majority of investors with good performance.
26. Is it compliant that the dividend exceeds the net profit?
The company formulated the dividend plan in strict accordance with relevant laws, regulations and other rules and regulations, which was reviewed and approved at the fifth meeting of the Fifth Board of directors. This dividend plan also needs to be reviewed at the annual general meeting of shareholders.
27. When will the equity registration date of dividends be announced?
The equity registration date of dividends will be announced and determined after the shareholders’ meeting deliberates and approves the dividend plan.
